NuCana
Yahoo Finance • 15 days ago
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with A... Full story
Yahoo Finance • 24 days ago
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering... Full story
Yahoo Finance • last month
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana”... Full story
Yahoo Finance • 3 months ago
NuCana receives compliance notification from Nasdaq
* NuCana (NASDAQ:NCNA [https://seekingalpha.com/symbol/NCNA]) on Friday said it has received formal notification from Nasdaq, confirming that the company is in compliance with all applicable continued listing criteria, including the $1.0... Full story
Yahoo Finance • 3 months ago
NuCana Compliant with All Nasdaq Continued Listing Criteria
EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the... Full story
Yahoo Finance • 3 months ago
NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
EDINBURGH, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced a presentation at the upcoming annual European Society for Medical Oncology (“ESMO”) congress being held Octobe... Full story
Yahoo Finance • 3 months ago
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Addit... Full story
Yahoo Finance • 3 months ago
H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress
Investing.com - H.C. Wainwright raised its price target on Editas Medicine (NASDAQ:EDIT) to $5.00 from $3.00 on Friday, while maintaining a Buy rating on the gene editing company’s stock. The upgrade comes as Editas shares have surged over... Full story
Yahoo Finance • 4 months ago
Most active stocks in Monday's session
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today. [mostactive] TODAY'S MOST ACTIVE STOCKS TICKER CHANGE COMMENT OPEN [https://www.chartmill.com/stock/qu... Full story
Yahoo Finance • 4 months ago
Discover the most active stocks in Tuesday's session.
Curious about the most active stocks on Tuesday? Find out which stocks are dominating the market action! [mostactive] MOST ACTIVE STOCKS TICKER CHANGE COMMENT GIBO [https://www.chartmill.com/stock/quote/GIBO/profile] 44.2%... Full story
Yahoo Finance • 4 months ago
These stocks are making the most noise in today's session.
These stocks are making the most noise in today's session. Stay tuned for the latest updates! [mostactive] TODAY'S MOST ACTIVE STOCKS TICKER CHANGE COMMENT GIBO [https://www.chartmill.com/stock/quote/GIBO/profile] 24.36%... Full story
Yahoo Finance • 4 months ago
Thursday's session: most active stocks
These stocks are making the most noise in today's session. Stay tuned for the latest updates! [mostactive] MOST ACTIVE STOCKS TICKER CHANGE COMMENT HCTI [https://www.chartmill.com/stock/quote/HCTI/profile] 74.6% So far, a... Full story
Yahoo Finance • 4 months ago
NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
EDINBURGH, United Kingdom, July 21, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces it has successfully canceled all remaining Series A Warrants, issued in the registered direct offering on May 7,... Full story
Yahoo Finance • 5 months ago
NuCana to implement 1:200 reverse ADS split to boost share price
EDINBURGH - NuCana plc (NASDAQ:NCNA) announced Friday it will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from 1:25 to 1:5,000, effectively creating a 1:200 reverse ADS split. According to InvestingPro data... Full story
Yahoo Finance • 5 months ago
NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, July 11, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, re... Full story
Yahoo Finance • 5 months ago
NuCana CEO takes leave of absence due to health reasons
NuCana plc (NASDAQ:NCNA) announced today that Chief Executive Officer Hugh S. Griffith will be taking a leave of absence due to health reasons, effective immediately. Griffith is expected to return to his duties later this year. The comp... Full story
Yahoo Finance • 6 months ago
NuCana GAAP EPS of -£0.02
* NuCana press release [https://seekingalpha.com/pr/20123467-nucana-reports-first-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:NCNA [https://seekingalpha.com/symbol/NCNA]): Q1 GAAP EPS of -£0.02. * As of March 3... Full story
Yahoo Finance • 6 months ago
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data... Full story
Yahoo Finance • 8 months ago
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory... Full story
Yahoo Finance • last year
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.55%
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Consumer Services, Consumer Goods and Industrials sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average added 0.55% to hit a ne... Full story
